Precision Oncology News

In Precision Oncology, Drugs Coming to Market Based on Smaller, Early-Phase, Single-Arm Trials

Premium

JP Morgan Healthcare, Day 4: Five Prime Therapeutics and Gritstone Oncology

NTRK Fusion Drug Not Cost Effective for Tumor-Agnostic Use, UK's NICE Suggest

National Institute for Health and Care Excellence draft guidance suggests more data is needed before using larotrectinib to treat UK cancer cases in histology-independent setting.

Genetic Testing Challenges in Oncology: Patient Told Genetic Test was Negative Turns out to be MAP Carrier

FDA Accepts Clovis Oncology's Supplemental Drug Application for Rubraca in Advanced Prostate Cancer

The FDA granted priority review status to rucaparib for prostate cancer patients with BRCA1/2 mutations.

Business & Policy

UK's NICE Will Not Recommend Osimertinib for Untreated Non-Small Cell Lung Cancer

Based on cost-effectiveness estimates and a lack of comparison against afatinib, NICE will recommend against using osimertinib for first-line treatment of NSCLC.

FDA Accepts Bridge Biotherapeutics' Investigational New Drug Application for Lung Cancer Drug

Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera

Technology

B Cell Gene Expression Profiling May Enable Cancer Immunotherapy CDx Test

Premium

Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

Immunotherapy Response Prediction Improves With TMB Correction, Other Markers

Premium

Diagnostics

B Cell Gene Expression Profiling May Enable Cancer Immunotherapy CDx Test

Premium

Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

FDA Accepts Bridge Biotherapeutics' Investigational New Drug Application for Lung Cancer Drug

Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

Medical Conditions

B Cell Gene Expression Profiling May Enable Cancer Immunotherapy CDx Test

Premium

Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.

UK's NICE Will Not Recommend Osimertinib for Untreated Non-Small Cell Lung Cancer

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

T Cell Assessment in Primary Melanomas Can Help Predict Metastatic Recurrence